Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Polaris Venture Partners V, L.P.. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Polaris Venture Partners V, L.P. har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:ADGI / Adagio Therapeutics Inc | 3.120.194 | |
US:LYRA / Lyra Therapeutics, Inc. | 10% Owner | 0 |
US:PHR / Phreesia, Inc. | 10% Owner | 31.015 |
US:CDLX / Cardlytics, Inc. | 10% Owner | 21.331 |
US:PULM / Pulmatrix, Inc. | 10% Owner | 7.700 |
US:ASNS / Actelis Networks, Inc. | 10% Owner | 0 |
US:SELB / Selecta Biosciences Inc | 10% Owner | 0 |
US:TTOO / T2 Biosystems, Inc. | 10% Owner | 2.030.917 |
US:GNCA / Genocea Biosciences Inc | 10% Owner | 1.968.606 |
US:LIFE / aTyr Pharma, Inc. | 10% Owner | 0 |
US:OCUL / Ocular Therapeutix, Inc. | 10% Owner | 19.588 |
US:TRVN / Trevena, Inc. | 10% Owner | 36.369 |
US:CERU / Cerulean Pharma Inc. | 10% Owner | 25.092 |
US:FATE / Fate Therapeutics, Inc. | 10% Owner | 0 |
US:BIND / BIND Therapeutics, Inc. | 10% Owner | 0 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Polaris Venture Partners V, L.P.. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ATYR / aTyr Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATYR / aTyr Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CDLX / Cardlytics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CDLX / Cardlytics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb DARE / Daré Bioscience, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-04-15 | CERU | Polaris Venture Management Co. V, L.L.C. | 1.470.582 | 7,0000 | 1.470.582 | 7,0000 | 10.294.074 | 731 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg DARE / Daré Bioscience, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb FATE / Fate Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg FATE / Fate Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GNCAQ / Genocea Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-02-10 | GNCA | Polaris Venture Management Co. V, L.L.C. | 232.820 | 12,0000 | 29.102 | 96,0000 | 2.793.840 | 130 | 181.6 | 2.491.083 | 89,16 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GNCAQ / Genocea Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb IVVD / Invivyd, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg IVVD / Invivyd, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LYRA / Lyra Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LYRA / Lyra Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb OCUL / Ocular Therapeutix, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg OCUL / Ocular Therapeutix, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PHR / Phreesia, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PHR / Phreesia, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PULM / Pulmatrix, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PULM / Pulmatrix, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RNAC / Cartesian Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RNAC / Cartesian Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRVN / Trevena, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATYR / aTyr Pharma, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-02-05 | TRVN | Polaris Venture Management Co. V, L.L.C. | 472.405 | 7,0000 | 18.896 | 175,0000 | 3.306.835 | 28 | 241 | 1.247.101 | 37,71 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRVN / Trevena, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATYR / aTyr Pharma, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Polaris Venture Partners V, L.P. som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
3.120.194 | ||||||||
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
60.814 | ||||||||
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
21.374 | ||||||||
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
31.198 | ||||||||
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
4.800.460 | ||||||||
2022-03-30 | 3 | ADGI |
Adagio Therapeutics, Inc.
Common Stock |
497.660 | ||||||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -118 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -173 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -337 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -17.304 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -13.625 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -19.890 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -38.765 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.988.991 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -43.966 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -64.183 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -125.094 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.418.387 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock |
C - Conversion | -52.700 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock |
C - Conversion | -76.934 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock |
C - Conversion | -149.944 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock |
C - Conversion | -7.693.406 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -58.980 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -86.101 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -167.809 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -8.610.081 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -22.580 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -32.961 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -64.237 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -3.296.014 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock |
C - Conversion | -42.941 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock |
C - Conversion | -62.687 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock |
C - Conversion | -122.177 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock |
C - Conversion | -6.268.687 | 0 | -100,00 | ||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 413 | 7.274 | 6,02 | 16,00 | 6.608 | 116.384 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 603 | 10.618 | 6,02 | 16,00 | 9.648 | 169.888 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1.176 | 20.701 | 6,02 | 16,00 | 18.816 | 331.216 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 60.308 | 1.062.259 | 6,02 | 16,00 | 964.928 | 16.996.144 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -64 | 6.861 | -0,92 | 16,00 | -1.024 | 109.776 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 118 | 6.925 | 1,73 | 8,63 | 1.018 | 59.763 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -94 | 10.015 | -0,93 | 16,00 | -1.504 | 160.240 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 173 | 10.109 | 1,74 | 8,63 | 1.493 | 87.241 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -182 | 19.525 | -0,92 | 16,00 | -2.912 | 312.400 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 337 | 19.707 | 1,74 | 8,63 | 2.908 | 170.071 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -9.334 | 1.001.951 | -0,92 | 16,00 | -149.344 | 16.031.216 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 17.304 | 1.011.285 | 1,74 | 8,63 | 149.334 | 8.727.390 | |
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 6.807 | 6.807 | |||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9.936 | 9.936 | |||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 19.370 | 19.370 | |||||
2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 993.981 | 993.981 | |||||
2019-12-18 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -3.446 | 31.015 | -10,00 | 24,48 | -84.355 | 759.216 | |
2019-12-18 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -2.360 | 21.245 | -10,00 | 24,48 | -57.770 | 520.056 | |
2019-12-18 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -6.716 | 60.446 | -10,00 | 24,48 | -164.401 | 1.479.658 | |
2019-12-18 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -344.599 | 3.101.386 | -10,00 | 24,48 | -8.435.439 | 75.918.828 | |
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Junior Convertible Preferred Stock |
C - Conversion | -84.134 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Junior Convertible Preferred Stock |
C - Conversion | -57.631 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Junior Convertible Preferred Stock |
C - Conversion | -163.973 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Junior Convertible Preferred Stock |
C - Conversion | -8.413.256 | 0 | -100,00 | ||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -3.828 | 34.461 | -10,00 | 18,00 | -68.904 | 620.298 | |
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -2.622 | 23.605 | -10,00 | 18,00 | -47.196 | 424.890 | |
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -7.462 | 67.162 | -10,00 | 18,00 | -134.316 | 1.208.916 | |
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
S - Sale | -382.887 | 3.445.985 | -10,00 | 18,00 | -6.891.966 | 62.027.730 | |
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
C - Conversion | 38.289 | 38.289 | |||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
C - Conversion | 26.227 | 26.227 | |||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
C - Conversion | 74.624 | 74.624 | |||||
2019-07-24 |
|
4 | PHR |
Phreesia, Inc.
Common Stock |
C - Conversion | 3.828.872 | 3.828.872 | |||||
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -268 | 21.331 | -1,24 | 27,45 | -7.356 | 585.472 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -183 | 14.595 | -1,24 | 27,45 | -5.023 | 400.589 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -552 | 41.532 | -1,31 | 27,45 | -15.151 | 1.139.929 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -26.778 | 2.131.187 | -1,24 | 27,45 | -734.976 | 58.494.690 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -202 | 21.599 | -0,93 | 27,87 | -5.630 | 601.940 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -139 | 14.778 | -0,93 | 27,87 | -3.874 | 411.847 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -394 | 42.054 | -0,93 | 27,87 | -10.980 | 1.171.999 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -20.227 | 2.157.965 | -0,93 | 27,87 | -563.704 | 60.140.111 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -193 | 21.801 | -0,88 | 27,73 | -5.351 | 604.452 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -132 | 14.917 | -0,88 | 27,73 | -3.660 | 413.587 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -376 | 42.448 | -0,88 | 27,73 | -10.425 | 1.176.909 |
2019-07-17 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | X | -19.283 | 2.178.192 | -0,88 | 27,73 | -534.639 | 60.392.334 |
2019-06-11 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -965 | 21.994 | -4,20 | 25,62 | -24.724 | 563.513 | |
2019-06-11 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -661 | 15.049 | -4,21 | 25,62 | -16.936 | 385.573 | |
2019-06-11 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -1.881 | 42.824 | -4,21 | 25,62 | -48.193 | 1.097.202 | |
2019-06-11 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -96.493 | 2.197.475 | -4,21 | 25,62 | -2.472.266 | 56.301.946 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -3 | 22.959 | -0,01 | 25,00 | -75 | 573.975 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -2 | 15.710 | -0,01 | 25,00 | -50 | 392.750 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -6 | 44.705 | -0,01 | 25,00 | -150 | 1.117.625 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -294 | 2.293.968 | -0,01 | 25,00 | -7.350 | 57.349.200 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -7 | 22.962 | -0,03 | 25,30 | -177 | 581.005 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -307 | 22.969 | -1,32 | 24,99 | -7.673 | 574.069 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -37 | 23.276 | -0,16 | 23,64 | -875 | 550.314 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -14 | 15.712 | -0,09 | 25,29 | -354 | 397.367 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -211 | 15.726 | -1,32 | 25,00 | -5.275 | 393.170 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -30 | 15.937 | -0,19 | 23,64 | -709 | 376.751 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -42 | 44.711 | -0,09 | 25,30 | -1.063 | 1.131.264 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -604 | 44.753 | -1,33 | 24,99 | -15.093 | 1.118.297 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -80 | 45.357 | -0,18 | 23,63 | -1.891 | 1.071.936 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -1.036 | 2.294.262 | -0,05 | 25,30 | -26.213 | 58.050.564 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -32.294 | 2.295.298 | -1,39 | 24,99 | -807.124 | 57.366.383 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -3.939 | 2.327.592 | -0,17 | 23,63 | -93.060 | 54.989.827 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -351 | 23.313 | -1,48 | 23,28 | -8.172 | 542.766 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -240 | 15.967 | -1,48 | 23,28 | -5.588 | 371.739 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -684 | 45.437 | -1,48 | 23,28 | -15.925 | 1.057.851 | |
2019-06-06 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -35.103 | 2.331.531 | -1,48 | 23,28 | -817.258 | 54.282.005 | |
2019-05-30 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -965 | 23.664 | -3,92 | 23,04 | -22.232 | 545.174 | |
2019-05-30 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -661 | 16.207 | -3,92 | 23,04 | -15.228 | 373.378 | |
2019-05-30 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -1.881 | 46.121 | -3,92 | 23,04 | -43.335 | 1.062.540 | |
2019-05-30 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -96.493 | 2.366.634 | -3,92 | 23,04 | -2.223.015 | 54.522.751 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -26 | 24.629 | -0,11 | 26,41 | -687 | 650.526 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -456 | 24.655 | -1,82 | 25,52 | -11.636 | 629.122 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -17 | 16.868 | -0,10 | 26,42 | -449 | 445.568 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -314 | 16.885 | -1,83 | 25,52 | -8.012 | 430.855 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -49 | 48.002 | -0,10 | 26,41 | -1.294 | 1.267.877 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -891 | 48.051 | -1,82 | 25,52 | -22.736 | 1.226.117 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -2.504 | 2.463.127 | -0,10 | 26,41 | -66.138 | 65.058.573 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -45.743 | 2.465.631 | -1,82 | 25,52 | -1.167.224 | 62.915.506 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -205 | 25.111 | -0,81 | 25,19 | -5.165 | 632.621 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -760 | 25.316 | -2,91 | 24,67 | -18.749 | 624.546 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -143 | 17.199 | -0,82 | 25,19 | -3.602 | 433.191 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -518 | 17.342 | -2,90 | 24,67 | -12.779 | 427.810 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -404 | 48.942 | -0,82 | 25,19 | -10.176 | 1.232.751 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -1.477 | 49.346 | -2,91 | 24,67 | -36.436 | 1.217.316 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -20.688 | 2.511.374 | -0,82 | 25,19 | -521.089 | 63.256.488 | |
2018-09-14 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
S - Sale | -75.805 | 2.532.062 | -2,91 | 24,67 | -1.870.109 | 62.465.970 | |
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
M - Exercise | -641 | 0 | -100,00 | ||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
M - Exercise | -438 | 0 | -100,00 | ||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
M - Exercise | -1.247 | 0 | -100,00 | ||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
M - Exercise | -64.038 | 0 | -100,00 | ||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
M - Exercise | 641 | 26.076 | 2,52 | 0,00 | 0 | 10 | |
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
M - Exercise | 438 | 17.860 | 2,51 | 0,00 | 0 | 7 | |
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
M - Exercise | 1.247 | 50.823 | 2,52 | 0,00 | 0 | 20 | |
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
M - Exercise | 64.038 | 2.607.867 | 2,52 | 0,00 | 26 | 1.043 | |
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
A - Award | 641 | 641 | |||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
A - Award | 438 | 438 | |||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
A - Award | 1.247 | 1.247 | |||||
2018-08-09 |
|
4 | CDLX |
Cardlytics, Inc.
Warrant (Right to Buy) |
A - Award | 64.038 | 64.038 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 7.700 | 7.700 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 7.700 | 7.700 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 5.275 | 5.275 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 5.275 | 5.275 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 15.007 | 15.007 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 15.007 | 15.007 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 769.989 | 769.989 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 769.989 | 769.989 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 6.478 | 6.478 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 6.478 | 6.478 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series A Warrant (right to buy) |
P - Purchase | 345.551 | 345.551 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Series B Warrant (right to buy) |
P - Purchase | 345.551 | 345.551 | |||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 7.700 | 34.587 | 28,64 | ||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 5.275 | 23.875 | 28,36 | ||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 15.007 | 67.729 | 28,46 | ||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 769.989 | 3.468.190 | 28,54 | ||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 6.478 | 29.178 | 28,54 | ||||
2018-04-05 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 345.551 | 1.556.676 | 28,53 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G? Redeemable Convertible Preferred Stock |
C - Conversion | -2.050 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G? Redeemable Convertible Preferred Stock |
C - Conversion | -1.404 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G? Redeemable Convertible Preferred Stock |
C - Conversion | -3.995 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G? Redeemable Convertible Preferred Stock |
C - Conversion | -205.020 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G Redeemable Convertible Preferred Stock |
C - Conversion | -280 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G Redeemable Convertible Preferred Stock |
C - Conversion | -191 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G Redeemable Convertible Preferred Stock |
C - Conversion | -545 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series G Redeemable Convertible Preferred Stock |
C - Conversion | -27.988 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series E-R Redeemable Convertible Preferred Stock |
C - Conversion | -255 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series E-R Redeemable Convertible Preferred Stock |
C - Conversion | -175 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series E-R Redeemable Convertible Preferred Stock |
C - Conversion | -498 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series E-R Redeemable Convertible Preferred Stock |
C - Conversion | -25.571 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series D-R Redeemable Convertible Preferred Stock |
C - Conversion | -1.644 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series D-R Redeemable Convertible Preferred Stock |
C - Conversion | -1.126 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series D-R Redeemable Convertible Preferred Stock |
C - Conversion | -3.205 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series D-R Redeemable Convertible Preferred Stock |
C - Conversion | -164.446 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series C-R Redeemable Convertible Preferred Stock |
C - Conversion | -4.176 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series C-R Redeemable Convertible Preferred Stock |
C - Conversion | -2.861 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series C-R Redeemable Convertible Preferred Stock |
C - Conversion | -8.140 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series C-R Redeemable Convertible Preferred Stock |
C - Conversion | -417.683 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series B-R Redeemable Convertible Preferred Stock |
C - Conversion | -9.311 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series B-R Redeemable Convertible Preferred Stock |
C - Conversion | -6.378 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series B-R Redeemable Convertible Preferred Stock |
C - Conversion | -18.148 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series B-R Redeemable Convertible Preferred Stock |
C - Conversion | -931.174 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series A-R Redeemable Convertible Preferred Stock |
C - Conversion | -7.719 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series A-R Redeemable Convertible Preferred Stock |
C - Conversion | -5.287 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series A-R Redeemable Convertible Preferred Stock |
C - Conversion | -15.045 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Series A-R Redeemable Convertible Preferred Stock |
C - Conversion | -771.947 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 2.050 | 25.435 | 8,77 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 1.404 | 17.422 | 8,77 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 3.995 | 49.576 | 8,76 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 205.020 | 2.543.829 | 8,77 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 280 | 23.385 | 1,21 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 191 | 16.018 | 1,21 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 545 | 45.581 | 1,21 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 27.988 | 2.338.809 | 1,21 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 255 | 23.105 | 1,12 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 175 | 15.827 | 1,12 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 498 | 45.036 | 1,12 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 25.571 | 2.310.821 | 1,12 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 1.644 | 22.850 | 7,75 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 1.126 | 15.652 | 7,75 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 3.205 | 44.538 | 7,75 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 164.446 | 2.285.250 | 7,75 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 4.176 | 21.206 | 24,52 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 2.861 | 14.526 | 24,53 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 8.140 | 41.333 | 24,52 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 417.683 | 2.120.804 | 24,52 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 9.311 | 17.030 | 120,62 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 6.378 | 11.665 | 120,64 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 18.148 | 33.193 | 120,62 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 931.174 | 1.703.121 | 120,63 | ||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 7.719 | 7.719 | |||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 5.287 | 5.287 | |||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 15.045 | 15.045 | |||||
2018-02-15 |
|
4 | CDLX |
Cardlytics, Inc.
Common Stock |
C - Conversion | 771.947 | 771.947 | |||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -21.537 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -14.752 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -41.976 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -2.153.746 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.213 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1.516 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -4.315 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -221.638 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -7.108 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -4.869 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -13.854 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -710.817 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -6.801 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -4.659 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -13.256 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -680.130 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -643 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -441 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1.254 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -64.329 | 0 | -100,00 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
P - Purchase | 4.825 | 18.031 | 36,54 | 10,00 | 48.250 | 180.310 | |
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
P - Purchase | 3.305 | 12.351 | 36,54 | 10,00 | 33.050 | 123.510 | |
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
P - Purchase | 9.403 | 35.146 | 36,53 | 10,00 | 94.030 | 351.460 | |
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
P - Purchase | 482.467 | 1.803.429 | 36,52 | 10,00 | 4.824.670 | 18.034.290 | |
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 6.310 | 13.206 | 91,50 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 4.322 | 9.046 | 91,49 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 12.298 | 25.743 | 91,47 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 631.041 | 1.320.962 | 91,47 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 1.102 | 6.896 | 19,02 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 755 | 4.724 | 19,02 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 2.150 | 13.445 | 19,03 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 110.312 | 689.921 | 19,03 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 3.173 | 5.794 | 121,06 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 2.173 | 3.969 | 120,99 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 6.185 | 11.295 | 121,04 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 317.376 | 579.609 | 121,03 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 2.433 | 2.621 | 1.294,15 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 1.667 | 1.796 | 1.292,25 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 4.743 | 5.110 | 1.292,37 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 243.385 | 262.233 | 1.291,30 | ||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 188 | 188 | |||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 129 | 129 | |||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 367 | 367 | |||||
2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 18.848 | 18.848 | |||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -157.957 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -1.579 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -1.082 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -3.078 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -238.470 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -2.384 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -1.632 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -4.647 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -226.801 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -2.267 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -1.553 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -4.420 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -609.316 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -6.093 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -4.174 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -11.875 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -333.207 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -3.332 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -2.282 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -6.494 | 0 | -100,00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 144.740 | 1.836.703 | 8,55 | 14,00 | 2.026.360 | 25.713.842 | |
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 1.448 | 18.364 | 8,56 | 14,00 | 20.272 | 257.096 | |
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 991 | 12.577 | 8,55 | 14,00 | 13.874 | 176.078 | |
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 2.821 | 35.793 | 8,56 | 14,00 | 39.494 | 501.102 | |
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 1.652.646 | 1.691.963 | 4.203,39 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 16.524 | 16.916 | 4.215,31 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 11.318 | 11.586 | 4.223,13 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 32.207 | 32.972 | 4.210,07 | ||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.507 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.010 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
41.134 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
80.059 | ||||||||
2015-08-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -10.367 | 2.030.917 | -0,51 | 15,02 | -155.713 | 30.504.576 |
2015-08-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -104 | 79.844 | -0,13 | 15,02 | -1.562 | 1.199.265 |
2015-08-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -71 | 58.001 | -0,12 | 15,02 | -1.066 | 871.181 |
2015-08-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -202 | 37.961 | -0,53 | 15,02 | -3.034 | 570.178 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -385 | 2.041.284 | -0,02 | 15,00 | -5.775 | 30.619.260 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -4 | 79.948 | -0,01 | 15,00 | -60 | 1.199.220 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -3 | 58.072 | -0,01 | 15,00 | -45 | 871.080 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -8 | 38.163 | -0,02 | 15,00 | -120 | 572.445 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.041.669 | -0,70 | 15,04 | -217.727 | 30.712.010 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 79.952 | -0,18 | 15,04 | -2.166 | 1.202.686 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.075 | -0,17 | 15,04 | -1.489 | 873.599 |
2015-07-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 38.171 | -0,73 | 15,04 | -4.242 | 574.191 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.056.143 | -0,70 | 15,22 | -220.357 | 31.303.338 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.096 | -0,18 | 15,22 | -2.192 | 1.219.406 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.174 | -0,17 | 15,22 | -1.507 | 885.658 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 38.453 | -0,73 | 15,22 | -4.293 | 585.420 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.070.617 | -0,69 | 15,42 | -223.202 | 31.930.778 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.240 | -0,18 | 15,42 | -2.221 | 1.237.373 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.273 | -0,17 | 15,42 | -1.527 | 898.622 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 38.735 | -0,72 | 15,42 | -4.349 | 597.329 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.085.091 | -0,69 | 16,05 | -232.340 | 33.470.298 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.384 | -0,18 | 16,05 | -2.312 | 1.290.340 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.372 | -0,17 | 16,05 | -1.589 | 936.999 |
2015-07-22 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 39.017 | -0,72 | 16,05 | -4.527 | 626.309 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.099.565 | -0,68 | 16,30 | -235.894 | 34.218.290 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.528 | -0,18 | 16,30 | -2.347 | 1.312.429 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.471 | -0,17 | 16,30 | -1.613 | 952.949 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 39.299 | -0,71 | 16,30 | -4.596 | 640.487 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.114.039 | -0,68 | 16,33 | -236.384 | 34.525.639 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.672 | -0,18 | 16,33 | -2.352 | 1.317.503 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.570 | -0,17 | 16,33 | -1.617 | 956.542 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 39.581 | -0,71 | 16,33 | -4.606 | 646.421 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.128.513 | -0,68 | 16,14 | -233.664 | 34.362.075 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.816 | -0,18 | 16,14 | -2.325 | 1.304.669 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.669 | -0,17 | 16,14 | -1.598 | 947.135 |
2015-07-17 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 39.863 | -0,70 | 16,14 | -4.553 | 643.536 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.142.987 | -0,67 | 16,54 | -239.419 | 35.447.791 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 80.960 | -0,18 | 16,54 | -2.382 | 1.339.184 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.768 | -0,17 | 16,54 | -1.638 | 972.099 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 40.145 | -0,70 | 16,54 | -4.665 | 664.050 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.157.461 | -0,67 | 16,60 | -240.206 | 35.804.576 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.104 | -0,18 | 16,60 | -2.390 | 1.345.978 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.867 | -0,17 | 16,60 | -1.643 | 976.939 |
2015-07-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 40.427 | -0,69 | 16,60 | -4.680 | 670.914 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.171.935 | -0,66 | 16,63 | -240.637 | 36.109.505 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.248 | -0,18 | 16,63 | -2.394 | 1.350.789 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 58.966 | -0,17 | 16,63 | -1.646 | 980.339 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 40.709 | -0,69 | 16,63 | -4.688 | 676.807 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.186.409 | -0,66 | 16,12 | -233.377 | 35.253.440 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.392 | -0,18 | 16,12 | -2.322 | 1.312.356 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.065 | -0,17 | 16,12 | -1.596 | 952.358 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 40.991 | -0,68 | 16,12 | -4.547 | 660.935 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.200.883 | -0,65 | 15,99 | -231.510 | 35.202.903 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.536 | -0,18 | 15,99 | -2.303 | 1.304.160 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.164 | -0,17 | 15,99 | -1.583 | 946.322 |
2015-07-10 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 41.273 | -0,68 | 15,99 | -4.511 | 660.158 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.215.357 | -0,65 | 16,23 | -234.913 | 35.955.244 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.680 | -0,18 | 16,23 | -2.337 | 1.325.666 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.263 | -0,17 | 16,23 | -1.607 | 961.838 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 41.555 | -0,67 | 16,23 | -4.577 | 674.438 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.229.831 | -0,64 | 15,98 | -231.305 | 35.634.260 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.824 | -0,18 | 15,98 | -2.301 | 1.307.605 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.362 | -0,17 | 15,98 | -1.582 | 948.646 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 41.837 | -0,67 | 15,98 | -4.507 | 668.585 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.244.305 | -0,64 | 15,51 | -224.424 | 34.798.622 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 81.968 | -0,18 | 15,51 | -2.233 | 1.270.938 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.461 | -0,17 | 15,51 | -1.535 | 921.961 |
2015-07-07 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 42.119 | -0,67 | 15,51 | -4.372 | 653.068 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.258.779 | -0,64 | 15,77 | -228.296 | 35.627.269 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.112 | -0,18 | 15,77 | -2.271 | 1.295.136 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.560 | -0,17 | 15,77 | -1.562 | 939.428 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 42.401 | -0,66 | 15,77 | -4.448 | 668.782 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.273.253 | -0,63 | 16,22 | -234.706 | 36.862.389 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.256 | -0,17 | 16,22 | -2.335 | 1.333.839 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.659 | -0,17 | 16,22 | -1.605 | 967.412 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 42.683 | -0,66 | 16,22 | -4.573 | 692.135 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.287.727 | -0,63 | 16,28 | -235.590 | 37.236.875 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.400 | -0,17 | 16,28 | -2.344 | 1.341.208 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.758 | -0,17 | 16,28 | -1.611 | 972.669 |
2015-07-01 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 42.965 | -0,65 | 16,28 | -4.590 | 699.333 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.302.201 | -0,62 | 16,76 | -242.594 | 38.586.500 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.544 | -0,17 | 16,76 | -2.414 | 1.383.495 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.857 | -0,17 | 16,76 | -1.659 | 1.003.245 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 43.247 | -0,65 | 16,76 | -4.727 | 724.850 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.316.675 | -0,62 | 16,85 | -243.932 | 39.043.155 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.688 | -0,17 | 16,85 | -2.427 | 1.393.549 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 59.956 | -0,16 | 16,85 | -1.668 | 1.010.444 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 43.529 | -0,64 | 16,85 | -4.753 | 733.599 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.331.149 | -0,62 | 17,61 | -254.929 | 41.058.294 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.832 | -0,17 | 17,61 | -2.536 | 1.458.912 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 60.055 | -0,16 | 17,61 | -1.744 | 1.057.743 |
2015-06-26 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 43.811 | -0,64 | 17,61 | -4.967 | 771.639 |
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 15.264 | 15.264 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 7.832 | 7.832 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 5.365 | 5.365 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 783.128 | 783.128 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 6.589 | 6.589 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 351.448 | 351.448 | |||||
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 1.392 | 52.722 | 2,71 | 6,88 | 9.570 | 362.464 | |
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 715 | 26.887 | 2,73 | 6,88 | 4.916 | 184.848 | |
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 490 | 18.600 | 2,71 | 6,88 | 3.369 | 127.875 | |
2015-06-25 |
|
4/A | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 71.439 | 2.698.201 | 2,72 | 6,88 | 491.143 | 18.550.132 | |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.345.623 | -0,61 | 18,15 | -262.664 | 42.566.724 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 82.976 | -0,17 | 18,15 | -2.613 | 1.505.790 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 60.154 | -0,16 | 18,15 | -1.797 | 1.091.633 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 44.093 | -0,64 | 18,15 | -5.118 | 800.169 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -14.474 | 2.360.097 | -0,61 | 18,22 | -263.671 | 42.993.651 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -144 | 83.120 | -0,17 | 18,22 | -2.623 | 1.514.189 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -99 | 60.253 | -0,16 | 18,22 | -1.803 | 1.097.623 |
2015-06-24 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
S - Sale | X | -282 | 44.375 | -0,63 | 18,22 | -5.137 | 808.375 |
2015-06-19 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -1.000 | 1.968.606 | -0,05 | 13,00 | -13.000 | 25.591.878 | |
2015-06-19 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -29.004 | 1.969.606 | -1,45 | 13,04 | -378.212 | 25.683.662 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Stock Option (Right to Buy) |
A - Award | 17.710 | 17.710 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 15.264 | 15.264 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 7.832 | 7.832 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 5.365 | 5.365 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 783.128 | 783.128 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 6.589 | 6.589 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Warrants to Purchase Common Stock |
A - Award | 351.448 | 351.448 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 1.392 | 52.692 | 2,71 | 6,88 | 9.570 | 362.258 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 51.330 | 51.330 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 714 | 26.886 | 2,73 | 6,88 | 4.909 | 184.841 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 26.172 | 26.172 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 489 | 18.599 | 2,70 | 6,88 | 3.362 | 127.868 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 18.110 | 18.110 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 71.438 | 2.698.200 | 2,72 | 6,88 | 491.136 | 18.550.125 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 2.626.762 | 2.626.762 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 601 | 22.700 | 2,72 | 6,88 | 4.132 | 156.062 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 22.099 | 22.099 | |||||
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
P - Purchase | 32.059 | 1.211.125 | 2,72 | 6,88 | 220.406 | 8.326.484 | |
2015-06-17 |
|
4 | PULM |
Pulmatrix, Inc.
Common Stock |
A - Award | 1.179.066 | 1.179.066 | |||||
2015-06-17 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -10.618 | 1.998.610 | -0,53 | 13,01 | -138.140 | 26.001.916 | |
2015-06-17 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -46.000 | 2.009.228 | -2,24 | 13,24 | -609.040 | 26.602.179 | |
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Redeemable Convertible Preferred Stock |
C - Conversion | -8.623 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Redeemable Convertible Preferred Stock |
C - Conversion | -5.906 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Redeemable Convertible Preferred Stock |
C - Conversion | -16.806 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Redeemable Convertible Preferred Stock |
C - Conversion | -862.318 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -14.706 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -10.074 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -28.661 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -1.470.577 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Redeemable Convertible Preferred Stock |
C - Conversion | -42.087 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Redeemable Convertible Preferred Stock |
C - Conversion | -28.831 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Redeemable Convertible Preferred Stock |
C - Conversion | -82.029 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Redeemable Convertible Preferred Stock |
C - Conversion | -4.208.756 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B-2 Redeemable Convertible Preferred Stock |
C - Conversion | -41.686 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B-2 Redeemable Convertible Preferred Stock |
C - Conversion | -28.556 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B-2 Redeemable Convertible Preferred Stock |
C - Conversion | -81.248 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B-2 Redeemable Convertible Preferred Stock |
C - Conversion | -4.168.683 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -34.737 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -23.796 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -67.704 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -3.473.763 | 0 | -100,00 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 890 | 17.638 | 5,31 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 610 | 12.082 | 5,32 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1.736 | 34.378 | 5,32 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 89.069 | 1.763.894 | 5,32 | ||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 16.748 | 16.748 | |||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 11.472 | 11.472 | |||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 32.642 | 32.642 | |||||
2015-05-14 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1.674.825 | 1.674.825 | |||||
2015-02-04 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
S - Sale | -4.824 | 19.588 | -19,76 | 29,50 | -142.308 | 577.846 | |
2015-02-04 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
S - Sale | -3.304 | 13.419 | -19,76 | 29,50 | -97.468 | 395.860 | |
2015-02-04 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
S - Sale | -9.403 | 38.178 | -19,76 | 29,50 | -277.388 | 1.126.251 | |
2015-02-04 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
S - Sale | -482.469 | 1.958.824 | -19,76 | 29,50 | -14.232.836 | 57.785.308 | |
2014-08-18 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -354 | 36.369 | -0,96 | 6,04 | -2.138 | 219.669 | |
2014-08-18 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -243 | 24.911 | -0,97 | 6,04 | -1.468 | 150.462 | |
2014-08-18 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -690 | 70.885 | -0,96 | 6,04 | -4.168 | 428.145 | |
2014-08-18 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -35.415 | 3.637.115 | -0,96 | 6,04 | -213.907 | 21.968.175 | |
2014-08-15 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -6.755 | 2.055.228 | -0,33 | 13,01 | -87.883 | 26.738.516 | |
2014-08-15 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -2.905 | 2.061.983 | -0,14 | 13,00 | -37.765 | 26.805.779 | |
2014-08-15 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -55 | 36.723 | -0,15 | 6,12 | -337 | 224.745 | |
2014-08-15 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -38 | 25.154 | -0,15 | 6,12 | -233 | 153.942 | |
2014-08-15 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -107 | 71.575 | -0,15 | 6,12 | -655 | 438.039 | |
2014-08-15 |
|
4 | TRVN |
TREVENA INC
Common Stock |
S - Sale | -5.500 | 3.672.530 | -0,15 | 6,12 | -33.660 | 22.475.884 | |
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -631.133 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -629.852 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -819.493 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.053.201 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -774.527 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -128.567 | 0 | -100,00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 2.291.307 | 2.374.571 | 2.751,86 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 22.912 | 83.264 | 37,96 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 15.695 | 60.352 | 35,15 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 44.657 | 44.657 | |||||
2014-08-12 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -20.990 | 2.064.888 | -1,01 | 13,03 | -273.500 | 26.905.491 | |
2014-08-12 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -1.428 | 2.085.878 | -0,07 | 13,24 | -18.907 | 27.617.025 | |
2014-08-12 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
S - Sale | -41.376 | 2.087.306 | -1,94 | 13,41 | -554.852 | 27.990.773 | |
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series D Preferred Stock |
C - Conversion | -24.181 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series D Preferred Stock |
C - Conversion | -16.565 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series D Preferred Stock |
C - Conversion | -47.131 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series D Preferred Stock |
C - Conversion | -2.418.191 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series C Preferred Stock |
C - Conversion | -40.268 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series C Preferred Stock |
C - Conversion | -27.584 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series C Preferred Stock |
C - Conversion | -78.483 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Series C Preferred Stock |
C - Conversion | -4.026.825 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 9.159 | 24.412 | 60,05 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 6.275 | 16.723 | 60,06 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 17.853 | 47.581 | 60,05 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 915.981 | 2.441.293 | 60,05 | ||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 15.253 | 15.253 | |||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 10.448 | 10.448 | |||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 29.728 | 29.728 | |||||
2014-07-31 |
|
4 | OCUL |
OCULAR THERAPEUTIX, INC
Common Stock |
C - Conversion | 1.525.312 | 1.525.312 | |||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Warrant to purchase Common Stock |
J - Other | 25.092 | 25.092 | |||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Warrant to purchase Series C |
J - Other | 0 | ||||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -6.793.234 | 0 | -100,00 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
7% Convertible Promissory Notes |
C - Conversion | 0 | ||||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
7% Convertible Promissory Notes |
C - Conversion | -2.698.039 | 0 | -100,00 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Series D Convertible Preferred Stock |
C - Conversion | -5.513.524 | 0 | -100,00 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.278.494 | 0 | -100,00 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
P - Purchase | 1.470.582 | 3.262.437 | 82,07 | 7,00 | 10.294.074 | 22.837.059 | |
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
C - Conversion | 401.061 | 1.791.855 | 28,84 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
C - Conversion | 385.435 | 1.390.794 | 38,34 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
C - Conversion | 380.044 | 1.005.359 | 60,78 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
C - Conversion | 157.052 | 625.315 | 33,54 | ||||
2014-04-15 |
|
4 | CERU |
Cerulean Pharma Inc.
Common Stock |
C - Conversion | 468.263 | 468.263 | |||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Warrants to purchase Series A Preferred Stock |
X - Other | -399.909 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Series C Preferred Stock |
C - Conversion | -6.075.152 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Series B Preferred Stock |
C - Conversion | -5.836.663 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Series A Preferred Stock |
C - Conversion | -8.393.754 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Seed Preferred Stock |
C - Conversion | -2.126.923 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
P - Purchase | 232.820 | 2.128.678 | 12,28 | 12,00 | 2.793.840 | 25.544.136 | |
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
C - Conversion | 10.781 | 1.895.858 | 0,57 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
C - Conversion | 510.516 | 1.885.077 | 37,14 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
C - Conversion | 490.474 | 1.374.561 | 55,48 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
C - Conversion | 705.356 | 884.087 | 394,65 | ||||
2014-02-11 |
|
4 | GNCA |
GENOCEA BIOSCIENCES, INC.
Common Stock |
C - Conversion | 178.731 | 178.731 | |||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series C Preferred Stock |
C - Conversion | -4.840.686 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
C - Conversion | -1.462.868 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
S - Sale | -487.132 | 62.868 | -88,57 | 1,13 | -549.972 | 70.978 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
X - Other | 550.000 | 550.000 | 1,00 | 550.000 | 550.000 | ||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Warrants- Purchase Series B-1 Preferred Stock (right to buy) |
X - Other | -550.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B Preferred Stock |
C - Conversion | -8.400.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series A Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 472.405 | 3.811.682 | 14,15 | 7,00 | 3.306.835 | 26.681.774 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 780.754 | 3.339.277 | 30,52 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 235.946 | 2.558.523 | 10,16 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 1.354.837 | 2.322.577 | 140,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 967.740 | 967.740 | |||||
2014-01-30 | 3 | TRVN |
TREVENA INC
Common Stock |
0 | ||||||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -5.506 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -5.506 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -3.772 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -3.772 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -10.732 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -10.732 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -550.653 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series C Convertible Preferred Stock |
C - Conversion | -550.653 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -2.227 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -2.227 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -1.525 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -1.525 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -4.340 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -222.677 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series A Convertible Preferred Stock |
C - Conversion | -6.518 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series A Convertible Preferred Stock |
C - Conversion | -4.465 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series A Convertible Preferred Stock |
C - Conversion | -12.704 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Series A Convertible Preferred Stock |
C - Conversion | -651.806 | 0 | -100,00 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
P - Purchase | 8.041 | 2.473.186 | 0,33 | 6,00 | 48.246 | 14.839.116 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
P - Purchase | 5.508 | 2.465.145 | 0,22 | 6,00 | 33.048 | 14.790.870 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
P - Purchase | 15.672 | 2.459.637 | 0,64 | 6,00 | 94.032 | 14.757.822 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
P - Purchase | 804.112 | 2.443.965 | 49,04 | 6,00 | 4.824.672 | 14.663.790 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
J - Other | 1.239 | 1.639.853 | 0,08 | 6,00 | 7.434 | 9.839.118 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
J - Other | 849 | 1.638.614 | 0,05 | 6,00 | 5.094 | 9.831.684 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
J - Other | 2.415 | 1.637.765 | 0,15 | 6,00 | 14.490 | 9.826.590 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
J - Other | 123.943 | 1.635.350 | 8,20 | 6,00 | 743.658 | 9.812.100 | |
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 2.560 | 1.511.407 | 0,17 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 12.024 | 1.508.847 | 0,80 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 1.753 | 1.496.823 | 0,12 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 8.237 | 1.495.070 | 0,55 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 4.988 | 1.486.833 | 0,34 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 23.436 | 1.481.845 | 1,61 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 255.950 | 1.458.409 | 21,29 | ||||
2013-10-07 |
|
4 | FATE |
FATE THERAPEUTICS INC
Common Stock |
C - Conversion | 1.202.459 | 1.202.459 | |||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series D Preferred Stock |
C - Conversion | -964.798 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C-1 Preferred Stock |
C - Conversion | -390.170 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C Preferred Stock |
C - Conversion | -487.780 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series B Preferred Stock |
C - Conversion | -1.900.000 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series A Preferred Stock |
C - Conversion | -1.476.960 | 0 | -100,00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
P - Purchase | 26.000 | 2.018.253 | 1,31 | 15,00 | 390.000 | 30.273.795 | |
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
C - Conversion | 1.992.253 | 1.992.253 |